Scientific paper - Original scientific paper
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, 20 (2022), 5; e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios; Talukder, Rafee; Lin, Genevieve Ihsiu; Diamantopoulos, Leonidas N.; Dawsey, Scott; Gupta, Shilpa; Carril-Ajuria, Lucia; Castellano, Daniel; de Kouchkovsky, Ivan; Koshkin, Vadim S.; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Tripathi, Nishita; Agarwal, Neeraj; Vather-Wu, Naomi; Zakharia, Yousef; Morales-Barrera, Rafael; Devitt, Michael E.; Cortellini, Alessio; Fulgenzi, Claudia Angela Maria; Pinato, David J.; Nelson, Ariel; Hoimes, Christopher J.; Gupta, Kavita; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana; Rodriguez-Vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Lu, Eric; Kumar, Vivek; Lorenzo, Giuseppe Di; Joshi, Monika; Isaacsson-Velho, Pedro; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Jang, Albert; Barata, Pedro; Sonpavde, Guru; Yu, Evan Y.; Montgomery, Robert Bruce; Grivas, Petros; Khaki, Ali Raza More authors...

Cite this document

Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S. ... Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 20. (5), e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer, vol. 20, no. 5, 2022, pp. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril Ajuria, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer 20, no. 5 (2022): e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, D., et al. (2022) 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, 20(5), pp. e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, and sur.. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer [Internet]. 2022 October [cited 2024 October 26];20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001

D. Makrakis, et al., "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma", Clinical Genitourinary Cancer, vol. 20, no. 5, pp. e440-e452, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:400491. [Accessed: 26 October 2024]

Please login to the repository to save this object to your list.